Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ortho Tri-Cyclen Lo is a combination hormonal contraceptive medication containing norgestimate and ethinyl estradiol. It's primarily used to prevent pregnancy and is available in a triphasic formulation with varying doses of norgestimate throughout the menstrual cycle, while maintaining a consistent dose of ethinyl estradiol. ## Composition and Formulation Ortho Tri-Cyclen Lo consists of 28 tablets in the following sequence: - 7 white tablets: 0.180 mg norgestimate and 0.025 mg ethinyl estradiol - 7 light blue tablets: 0.215 mg norgestimate and 0.025 mg ethinyl estradiol - 7 dark blue tablets: 0.250 mg norgestimate and 0.025 mg ethinyl estradiol - 7 dark green tablets: inert (hormone-free)[2][3][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ortho Tri-Cyclen Lo.